OSU Navigation Bar

The Ohio State University University Libraries Knowledge Bank

Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior

Please use this identifier to cite or link to this item: http://hdl.handle.net/1811/51665

Show full item record

Files Size Format View
fac_ArnoldE_JChildAdolescPsychopharm_2008_18_3.pdf 387.8Kb PDF View/Open

Title: Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Creators: Aman, Michael G.; Hollway, Jill A.; McDougle, Christopher J.; Scahill, Lawrence; Tierney, Elaine; McCracken, James T.; Arnold, L. Eugene; Vitiello, Benedetto; Ritz, Louise; Gavaletz, Allison; Cronin, Pegeen; Swiezy, Naomi; Wheeler, Courtney; Koenig, Kathleen; Ghuman, Jaswinder K.; Posey, David J.
Issue Date: 2008
Publisher: Mary Ann Liebert, Inc. Publishers
Citation: Michael G. Aman et al, "Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior," Journal of Child and Adolescent Psychopharmacology 18, no. 3 (2008), doi:10.1089/cap.2007.0133
DOI: 10.1089/cap.2007.0133
Abstract: Objective: The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior. Method: Thirty-eight children, ages 5-17 years with autism and severe behavioral disturbance, were randomly assigned to risperidone (0.5 to 3.5 mg/day) or placebo for 8 weeks. This sample of 38 was a subset of 101 subjects who participated in the clinical trial; 63 were unable to perform the cognitive tasks. A double-blind placebo-controlled parallel groups design was used. Dependent measures included tests of sustained attention, verbal learning, hand-eye coordination, and spatial memory assessed before, during, and after the 8-week treatment. Changes in performance were compared by repeated measures ANOVA. Results: Twenty-nine boys and 9 girls with autism and severe behavioral disturbance and a mental age ≥18 months completed the cognitive part of the study. No decline in performance occurred with risperidone. Performance on a cancellation task (number of correct detections) and a verbal learning task (word recognition) was better on risperidone than on placebo (without correction for multiplicity). Equivocal improvement also occurred on a spatial memory task. There were no significant differences between treatment conditions on the Purdue Pegboard (hand-eye coordination) task or the Analog Classroom Task (timed math test). Conclusion: Risperidone given to children with autism at doses up to 3.5 mg for up to 8 weeks appears to have no detrimental effect on cognitive performance.
ISSN: 1557-8992
URI: http://hdl.handle.net/1811/51665
Rights: © 2008 Mary Ann Liebert, Inc. Publishers
Bookmark and Share